Search Results
Your search for ,are matches 22257 pages
Showing 1 - 50FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 13, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with the antibody-drug conjugate enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after radical cystectomy, for the ...
Clinical Trial Participation Among Patients With Advanced Cancer Driven by Structural Factors at Physician and Practice Levels
Physician and oncology practice factors have greater influence over who gets enrolled in advanced cancer clinical trials than measured patient characteristics such as age, cancer type, and physical function, according to a recent study. The findings, published by Jiang et al in JAMA Network Open,...
American Cancer Society Updates Prostate Cancer Screening Guideline
Today, the American Cancer Society (ACS) released an updated guideline for prostate cancer screening. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based screening every 2 years for average-risk men aged 50 to 69 years, with clinicians ensuring patients understand...
Childhood Cancers: Survival Gains Reveal Progress and Persistent Disparities
Survival trends for children and young adults with cancer have improved over the years in the United States, with 5-year overall survival rates reaching 90% in 2017, according to comprehensive findings for U.S. childhood cancer survival statistics published in the Journal of the National Cancer...
Relapsed or Refractory CTCL: Denileukin Diftitox May Improve HRQoL
Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) receiving denileukin diftitox-cxdl demonstrated an improvement or maintenance of their overall health-related quality of life (HRQoL), according to findings from Study 302 presented at the European Organisation for Research and...
Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk
Scientists have carried out one of the largest experimental studies of breast cancer variants to date, helping pinpoint genetic changes that are most likely to contribute to the development of the disease. Researchers—led by a team at The Institute of Cancer Research, London—analyzed over 5,000...
FDA Approves Pimicotinib for Symptomatic TGCT
On November 10, the U.S. Food and Drug Administration (FDA) approved pimicotinib (Pimjetmi), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may cause worsening functional limitation or severe morbidity. MANEUVER Trial Efficacy was...
ASCO and ESMO Issue Joint Consensus Calling for Streamlined Clinical Research Under Updated International Standards
ASCO and the European Society for Medical Oncology (ESMO) have released a joint consensus statement highlighting strategies to reduce administrative burden and streamline cancer clinical trials. The statement focuses on leveraging newly updated guidelines from the International Council for...
Beyond Chemotherapy: Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC
Updated findings from Stage 1 of the multicenter, international, two-stage phase III PRESERVE-003 trial showed that, among patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease had progressed following anti–PD-(L)1 therapy, treatment with the investigational anti–CTLA-4 ...
Preventing Africa’s Coming Cancer Crisis: The Harm Reduction Imperative
Africa is heading toward a cancer catastrophe, and the oncology community must not look away. Noncommunicable diseases already account for 37% of all deaths in the WHO African Region, up from 24% in 2000, and nearly two-thirds of these deaths occur prematurely, before 70.1,2These are not distant...
First-Line T-DXd: A Change of DESTINY for HER2-Mutant NSCLC?
In patients with advanced HER2-mutant non–small cell lung cancer (NSCLC), first-line monotherapy with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) significantly prolonged progression-free survival compared with standard-of-care chemoimmunotherapy. This was...
Nobel Prize in Physiology or Medicine 2026 Awarded for Optogenetics
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth, MD, PhD, of The Howard Hughes Medical Institute and Stanford University, California; Peter Hegemann, PhD, of Humboldt University of Berlin, Germany; and Georg Nagel,...
U.S. Food and Drug Administration Expanded Indications and Approvals in Bladder and Colorectal Cancers
Several approvals by the U.S. Food and Drug Administration (FDA) over the past month included therapeutics for patients with BCG-unresponsive non–muscle-invasive bladder cancer and locally advanced rectal cancer. Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the FDA...
AI Diagnostics and What Clinicians Can Verify in Oncology
When artificial intelligence (AI) is applied to medical images, it can improve physicians’ diagnostic capabilities as well as identify features that humans are unable to see. From identifying biomarkers to guiding treatment decisions, AI in medical imaging has already demonstrated numerous...
Two ‘Forever Chemicals’ Associated With Higher Risk of ER-Negative Breast Cancer
Higher blood concentrations of two common per- and polyfluoroalkyl substances (PFAS) were associated with an increased incidence of estrogen receptor (ER)-negative breast cancer among women participating in the Sister Study, according to research published by Chang et al in the Journal of Clinical ...
ROSELLA Subgroup Analysis Supports Relacorilant Use in Patients Previously Treated With Taxanes
Can patients with platinum-resistant ovarian cancer treated with taxane therapy benefit from receiving relacorilant after a taxane? A new subgroup analysis from the phase III ROSELLA trial1 suggests the answer may be yes. The analysis, presented at the 2026 ASCO Annual Meeting, focused on prior...
Extended Follow-up of Nivolumab/Ipilimumab for Localized dMMR/MSI-H Gastric/GEJ Cancer
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival in patients with localized mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) gastric or gastroesophageal junction (GEJ) adenocarcinoma, based on updated...
American Lung Association and Prevent Cancer Foundation Host Virtual QIW Workshop: Advancing Routine Clinical Use of Health Information From Chest CT Screening for Public Health
The Quantitative Imaging Workshop (QIW) brings together leading experts from around the world for the advancement of quantitative low-dose computed tomography (CT) imaging biomarkers for detection and management of early chest diseases including lung cancer, chronic obstructive pulmonary disease,...
Pediatric Brain Tumors: Prognostic AI Model Guides Precision Therapy Choices
An artificial intelligence (AI) model built based on DNA methylation profiling provided a look at outcomes for children with medulloblastoma and ependymoma, according to study findings published in Nature Genetics. The model may be used to guide personalized treatment decisions, including treatment ...
Anthony B. El-Khoueiry, MD, Named Director of the USC Norris Comprehensive Cancer Center
Anthony B. El-Khoueiry, MD, has been appointed Director of the University of Southern California (USC) Norris Comprehensive Cancer Center, effective November 1. Prior to the appointment, Dr. El-Khoueiry served as Associate Director for Clinical Research, Medical Director of the Clinical...
Keeping PACE With Surgery: SBRT for Localized Prostate Cancer
An updated efficacy analysis of the international phase III PACE-A trial showed high rates of freedom from biochemical or clinical failure (BCF) with both stereotactic body radiation therapy (SBRT) and radical prostatectomy in patients with localized prostate cancer, with no statistically...
Basser Center for BRCA Awards 2026 Global Prize
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, has named Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, as the recipient of...
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
The EGFR and HER3 bispecific antibody–drug conjugate izalontamab brengitecan significantly improved progression-free survival vs chemotherapy in heavily pretreated Chinese patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the multicenter phase III...
IOF Issues Position Statement on Bone Fragility Management for Patients With MGUS
The International Osteoporosis Foundation (IOF) Committee of Scientific Advisors (CSA) Bone and Cancer Working Group has released a position statement on bone fragility in patients with monoclonal gammopathy of undetermined significance (MGUS). The new statement provides guidance on how to...
A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery
Patients preparing to undergo surgery for pancreatic adenocarcinoma who received stereotactic body radiation therapy (SBRT) appeared to have comparable pathologic and surgical outcomes while reporting better quality of life during treatment than those who received conventionally fractionated...
Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer
Neoadjuvant niraparib monotherapy produced tumor responses and enabled complete resection in selected patients with homologous recombination deficiency (HRD)-positive advanced ovarian cancer who were considered unlikely to achieve complete primary debulking surgery. Dan Liu, MD, and colleagues...
Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, the timing of progression is one of the factors Peter A. Riedell, MD, considers when choosing the next treatment. A long first remission may support another course of chemoimmunotherapy, but progression within 24 months of starting...
Study Reveals Distinct Cellular and Genetic Differences in Early-Onset Colorectal Cancer
Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, along with researchers at Dana-Farber Cancer Institute and the Broad Institute, have identified biological differences in colorectal tumors that may help explain why the disease can behave more aggressively ...
OptiTROP-Lung06: A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?
In patients with advanced PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC) without targetable genomic alterations, first-line treatment with the Trop-2–directed antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab demonstrated a significant progression-free survival...
ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO’s 2018 recommendations and reflects a...
Selpercatinib, Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes
Researchers from Vall d’Hebron University Hospital presented advances in targeted therapies for patients with thyroid cancer during the ESMO Congress 2026. Updated results of the phase III LIBRETTO-531 trial showed durable benefits with selpercatinib compared with existing targeted therapies for...
Disitamab Vedotin Plus Tislelizumab Shows Activity in Very High–Risk Non–Muscle-Invasive Bladder Cancer
Treatment with the anti-ERBB2 antibody-drug conjugate disitamab vedotin plus the anti–PD-1 immune checkpoint inhibitor tislelizumab-jsgr showed evidence of antitumor activity in patients with transurethrally unresectable, ERBB2-positive, very high–risk non–muscle invasive bladder cancer, according...
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
In 2024, ASCO updated its guideline for the integration of palliative care in oncology, which recommends that clinicians refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams beginning early in the course of a patient’s disease ...
TALENT: Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Neoadjuvant treatment with the HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki (T-DXd), given alone, with endocrine therapy, or followed by chemotherapy, produced pathologic complete response rates (pCR) in the single digits among patients with hormone receptor (HR)-positive,...
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
In patients with extensive-stage small cell lung cancer (SCLC), tarlatamab-dlle, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than 8 months, more than tripled progression-free survival, and reduced the risk of death by 58%...
TIL Therapy Plus Pembrolizumab for Advanced Melanoma
Patients with advanced melanoma achieved deep and durable responses after receiving the tumor-infiltrating lymphocyte (TIL) therapy lifileucel alongside the immune checkpoint inhibitor pembrolizumab as a first-line treatment, according to results from a new clinical trial. Approximately two-thirds...
Machine Learning Models Outperform Traditional Approaches to Multicancer Risk Prediction
Machine learning models using routine clinical data may be able to identify individuals at higher risk of developing several common cancers, according to findings from an international study presented at the ESMO Congress 2026 (Abstract 280RO). “For selected cancers, these models could serve as a...
ESMO 2026: Sacituzumab Tirumotecan vs Physician’s Choice of Treatment in Patients With Previously Treated Endometrial Cancer
Sacituzumab tirumotecan may extend both progression-free and overall survival compared with standard chemotherapy in patients with advanced or recurrent endometrial cancer, according to findings from the phase III TroFuse-005/ENGOT-en23/GOG-3095 trial presented at the ESMO Congress 2026 (Abstract...
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors?
A multicenter retrospective cohort study published by Yao et al in JAMA Surgery found that although pancreatic enucleation was associated with a higher rate of clinically relevant postoperative pancreatic fistula than pancreatoduodenectomy, it was linked to fewer major complications, less delayed...
Immunotherapy/PARP Inhibitor Combination Prolongs Survival in Advanced Endometrial Cancer
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson...
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
The addition of consolidation radiotherapy to first-line systemic anticancer therapy resulted in better local disease control and prolonged progression-free survival compared with systemic therapy alone in patients with synchronous oligometastaic non–small cell lung cancer (NSCLC) without an...
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
Patients with previously treated advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC) had improved progression-free and overall survival and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of...
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
Today, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor talazoparib (Talzenna) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR)...
GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer
Adults with diabetes and a history of cancer were less likely to report current use of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) than those without a cancer history, despite having higher rates of cardiovascular and kidney disease. Olinto Linares-Perdomo, PhD, and colleagues...
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer
Abiraterone acetate added to androgen-deprivation therapy and docetaxel resulted in a significant overall survival benefit compared with standard-of-care therapy alone in patients with de novo metastatic castration-sensitive prostate cancer, according to long-term findings from the phase III...
High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy May Benefit Outcomes After Surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract...
Real-World Data Are Not Necessarily Real-World Evidence
Real-world data (RWD) provide raw material from which real-world evidence (RWE) is generated, but the two terms are not synonymous. Over the past decade, RWD and RWE have become increasingly prominent in oncology. A search of the 2016 ASCO Annual Meeting abstracts identified 48 with terms “real...
Robert A. Kyle, MD, Renowned Expert in Myeloma, Dies at 98
The International Myeloma Foundation (IMF) shared news on the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly-revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
